NEWS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Immune Design Appoints Frank J. Hsu, M.D., Vice President, Head of Oncology
Immune Design Appoints Frank J. Hsu, M.D., Vice President, Head of Oncology SAN FRANCISCO, Oct. 24, 2013 (GLOBE NEWSWIRE) -- Immune Design, a biotech company focused on the development of novel immune-based therapies for cancer and other human diseases, today announced the appointment of Frank J.
View HTML
Toggle Summary Immune Design Appoints Jan Henrik ter Meulen, M.D., Chief Scientific Officer
Immune Design Appoints Jan Henrik ter Meulen, M.D., Chief Scientific Officer SEATTLE and SAN FRANCISCO, Oct. 1, 2013 (GLOBE NEWSWIRE) -- Immune Design, a biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced the
View HTML
Toggle Summary Immune Design Appoints Stephen R. Brady Chief Business Officer
Immune Design Appoints Stephen R. Brady Chief Business Officer SEATTLE and SAN FRANCISCO , Sept. 26, 2013 /PRNewswire/ -- Immune Design, a biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced the appointment
View HTML
Toggle Summary Immune Design Appoints Richard T. Kenney, M.D., Chief Medical Officer
Immune Design Appoints Richard T. Kenney, M.D., Chief Medical Officer SEATTLE, Sept. 5, 2013 (GLOBE NEWSWIRE) -- Immune Design, a biotech company focused on the development of novel immune-based therapies for cancer and other human diseases, today announced the appointment of Richard T.
View HTML
Toggle Summary Immune Design Partners with Top Cancer Organizations
Immune Design Partners with Top Cancer Organizations MEDIA RELEASE IMMUNE DESIGN PARTNERS WITH LEADING CANCER ORGANIZATIONS TO ADVANCE NOVEL IMMUNOTHERAPY RESEARCH The Cancer Research Institute, the Ludwig Institute for Cancer Research and Immune Design Form New Collaboration to Accelerate Clinical
View HTML
Toggle Summary Immune Design to Present at 3rd Annual Cancer Immunotherapy Conference
Immune Design to Present at 3rd Annual Cancer Immunotherapy Conference SEATTLE, Oct. 2, 2012 (GLOBE NEWSWIRE) -- Immune Design today announced that the company will be presenting at the 3 rd Annual Cancer Immunotherapy: A Long-Awaited Reality conference on Thursday, October 4, at 3:15 p.m.
View HTML
Toggle Summary Immune Design Corp. Announces Appointment of Dr. Roger Perlmutter as a Member of Its Board of Directors
Immune Design Corp. Announces Appointment of Dr. Roger Perlmutter as a Member of Its Board of Directors SEATTLE, June 26, 2012 (GLOBE NEWSWIRE) -- Immune Design Corp. announced today the appointment of Roger M. Perlmutter, M.D., Ph.D., as a member of its Board of Directors. Dr.
View HTML
Toggle Summary Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer SEATTLE , Dec. 2, 2011 /PRNewswire/ -- Immune Design Corp. announced today that Wayne R. Gombotz , Ph.D. has joined the company as its new Chief Development Officer.  Dr.
View HTML
Toggle Summary Immune Design Corp. and Sanofi-Aventis Announce Research Collaboration
Immune Design Corp. and Sanofi-Aventis Announce Research Collaboration SEATTLE , Oct. 26, 2011 /PRNewswire/ -- Immune Design Corp. (IDC), a privately held biotechnology company developing novel vaccines and immunotherapies for infectious disease, cancer and allergy, announced today that it has
View HTML
Toggle Summary Immune Design Corp. Appoints Pharma and Biotech Executive Carlos V. Paya, MD, PhD as Chief Executive Officer
Immune Design Corp. Appoints Pharma and Biotech Executive Carlos V. Paya, MD, PhD as Chief Executive Officer SEATTLE , April 27, 2011 /PRNewswire/ -- Immune Design Corp. (IDC) announced today that Carlos V. Paya , MD, PhD, will join IDC as Chief Executive Officer and Board Director effective May 2,
View HTML